Literature DB >> 26766937

Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections.

Amanda W Williams1, Patrick M Newman1, Sara Ocheltree2, Rachel Beaty3, Ali Hassoun2.   

Abstract

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is one of the most common pathogens causing pediatric infections including skin and soft tissue infections, pyogenic arthritis, osteomyelitis, and septic shock. For decades, patients were treated with antibiotics such as vancomycin and clindamycin, but there is an increasing incidence of resistance to these traditional therapies. We describe 2 cases of patients with CA-MRSA invasive infections with bacteremia who experienced vancomycin therapy failure but who were successfully treated with ceftaroline fosamil. Case 1 involves an 8-year-old Hispanic male who was diagnosed with CA-MRSA bacteremia, thigh abscess, and osteomyelitis. The patient was admitted to the pediatric intensive care unit in septic shock. Case 2 involves an 8-year-old Caucasian male who was diagnosed with CA-MRSA sepsis, right arm abscess, and osteomyelitis. We were able to successfully treat both patients with CA-MRSA sepsis and invasive infection-who failed vancomycin therapy-with ceftaroline fosamil with no adverse efiects. Despite the positive outcome in both pediatric patients, clinical trials with ceftaroline fosamil are needed to further support its use in pediatric patients.

Entities:  

Keywords:  ceftaroline fosamil; child; methicillin-resistant Staphylococcus aureus; osteomyelitis; pediatrics

Year:  2015        PMID: 26766937      PMCID: PMC4708957          DOI: 10.5863/1551-6776-20.6.476

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  8 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

Review 2.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

3.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Sheldon L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2014-07-15       Impact factor: 9.079

4.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

Authors:  G Ralph Corey; Mark H Wilcox; George H Talbot; Dirk Thye; David Friedland; Tanya Baculik
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

6.  Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.

Authors:  Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

Review 7.  Summary of ceftaroline fosamil clinical trial studies and clinical safety.

Authors:  Thomas M File; Mark H Wilcox; Gary E Stein
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

Review 8.  Trends in invasive methicillin-resistant Staphylococcus aureus infections.

Authors:  Martha Iwamoto; Yi Mu; Ruth Lynfield; Sandra N Bulens; Joelle Nadle; Deborah Aragon; Susan Petit; Susan M Ray; Lee H Harrison; Ghinwa Dumyati; John M Townes; William Schaffner; Rachel J Gorwitz; Fernanda C Lessa
Journal:  Pediatrics       Date:  2013-09-23       Impact factor: 7.124

  8 in total
  4 in total

Review 1.  Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.

Authors:  Juwon Yim; Leah M Molloy; Jason G Newland
Journal:  Infect Dis Ther       Date:  2016-12-30

Review 2.  Acute Hematogenous Osteomyelitis in Children: Clinical Presentation and Management.

Authors:  J Chase McNeil
Journal:  Infect Drug Resist       Date:  2020-12-14       Impact factor: 4.003

3.  In Vitro Testing of Crude Natural Plant Extracts from Costa Rica for Their Ability to Boost Innate Immune Cells against Staphylococcus aureus.

Authors:  Ragheda Yaseen; Katja Branitzki-Heinemann; Hani Moubasher; William N Setzer; Hassan Y Naim; Maren von Köckritz-Blickwede
Journal:  Biomedicines       Date:  2017-07-05

Review 4.  Panton-valentine leukocidin Staphylococcus aureus severe infection in an infant: a case report and a review of the literature.

Authors:  Massimo Luca Castellazzi; Samantha Bosis; Irene Borzani; Claudia Tagliabue; Raffaella Pinzani; Paola Marchisio; Giada Maria di Pietro
Journal:  Ital J Pediatr       Date:  2021-07-17       Impact factor: 2.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.